AtriCure CFO Sees 12%-14% Organic Growth in 2026 as Pain Management Adoption Accelerates

Company expects strong contributions from recent product launches, particularly in cardiac pain management

Mar. 11, 2026 at 9:44am

Got story updates? Submit your updates here. ›

AtriCure CFO Angie Wirick outlined the company's early expectations for 2026 growth, projecting 12%-14% organic revenue growth driven by continued momentum across its cardiac surgery and pain management franchises. Wirick cited strong adoption of the EnCompass clamp, which has helped simplify and accelerate cardiac procedures, as well as product iterations in the company's cryoSPHERE pain management platform that have reduced freeze times per nerve. AtriCure is also expanding into post-operative amputation pain management with a dedicated device.

Why it matters

AtriCure's growth outlook reflects the company's ability to drive adoption of its innovative surgical ablation and pain management technologies, which have the potential to improve patient outcomes and reduce procedure times in cardiac surgery. The company's focus on expanding its addressable market, such as into the large amputation pain management opportunity, also demonstrates its strategic vision.

The details

Wirick said the company's initial 2026 organic revenue growth guide of 12% to 14% represents a 'slight uptick' from 2025, driven by recent product launches. The strongest expected contribution is coming from pain management, where the company has made improvements to reduce procedure times. For its cardiac surgery business, Wirick noted growing adoption of the EnCompass clamp, which has helped simplify procedures. She also discussed AtriCure's efforts to expand treatment to cardiac surgery patients without a preexisting Afib diagnosis through the LeAAPS and BoxX-NoAF clinical trials.

  • Enrollment in the LeAAPS trial began in January 2023 and completed in July 2025, about two years faster than anticipated.
  • As of the company's most recent quarterly update, AtriCure had reached the 50% mark toward required events for the LeAAPS trial.

The players

Angie Wirick

CFO of AtriCure, a medical device company focused on treatments for atrial fibrillation and related conditions.

AtriCure, Inc.

A medical device company focused on the development, manufacture and marketing of innovative therapies to treat atrial fibrillation and related conditions.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident

“Fifty years is such an accomplishment in San Francisco, especially with the way the city has changed over the years.”

— Gordon Edgar, grocery employee

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This case highlights growing concerns in the community about repeat offenders released on bail, raising questions about bail reform, public safety on SF streets, and if any special laws to govern autonomous vehicles in residential and commercial areas.